Immunomodulatory properties of mesenchymal stem cells

A review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005

Alan Tyndall*, Ulrich A. Walker, Andrew Cope, Francesco Dazzi, Cosimo De Bari, Willem Fibbe, Serena Guiducci, Simon Jones, Christian Jorgensen, Katarina Le Blanc, Frank Luyten, Dennis McGonagle, Ivan Martin, Chiara Bocelli-Tyndall, Giuseppina Pennesi, Vito Pistoia, Constantino Pitzalis, Antonio Uccelli, Nico Wulffraat, Marc Feldmann

*Corresponding author for this work

Research output: Contribution to journalArticle

124 Citations (Scopus)


Multipotent mesenchymal stromal cells isolated from bone marrow and other sites are currently being studied to determine their potential role in the pathogenesis and/or management of autoimmune diseases. In vitro studies have shown that they exhibit a dose-dependent antiproliferative effect on T and B lymphocytes, dendritic cells, natural killer cells and various B cell tumour lines - an effect that is both cell contact and soluble factor dependent. Animal models of autoimmune disease treated with multipotent mesenchymal stromal cells have mostly exhibited a positive clinical response, as have a limited number of patients suffering from acute graft versus host disease. This review summarizes the findings of a 1-day meeting devoted to the subject with the aim of coordinating efforts.

Original languageEnglish
Pages (from-to)301-310
Number of pages10
JournalArthritis Research and Therapy
Issue number1
Publication statusPublished - 29 Jan 2007


Cite this